Silk Road Medical Inc SILK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SILK is a good fit for your portfolio.
News
-
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
-
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
-
Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
-
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
-
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
-
Silk Road Medical stock falls following outlook, CEO's retirement
-
Silk Road Medical stock tanks after CMS decision on carotid artery stenting prompts analyst downgrade
Trading Information
- Previous Close Price
- $17.71
- Day Range
- $17.37–17.95
- 52-Week Range
- $6.08–46.57
- Bid/Ask
- $15.00 / $18.29
- Market Cap
- $683.99 Mil
- Volume/Avg
- 373,772 / 816,240
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy. The company generates all of its revenue in the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 474
- Website
- https://www.silkroadmed.com
Comparables
Valuation
|
Metric
|
SILK
|
SIBN
|
PRCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.59 | 3.69 | 9.40 |
Price/Sales | 3.88 | 4.24 | 18.04 |
Price/Cash Flow | — | — | — |
Price/Earnings
SILK
SIBN
PRCT
Financial Strength
|
Metric
|
SILK
|
SIBN
|
PRCT
|
|---|---|---|---|
Quick Ratio | 6.77 | 8.01 | 6.65 |
Current Ratio | 7.95 | 9.01 | 7.63 |
Interest Coverage | −8.56 | −13.52 | −27.40 |
Quick Ratio
SILK
SIBN
PRCT
Profitability
|
Metric
|
SILK
|
SIBN
|
PRCT
|
|---|---|---|---|
Return on Assets (Normalized) | −6.33% | −8.97% | −25.31% |
Return on Equity (Normalized) | −10.68% | −12.61% | −38.72% |
Return on Invested Capital (Normalized) | −8.48% | −11.78% | −29.67% |
Return on Assets
SILK
SIBN
PRCT
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Jhwqnzbbg | Wngfsr | $183.8 Bil | |
SYK
| Stryker Corp | Jjjrzmtsb | Bxzv | $127.8 Bil | |
MDT
| Medtronic PLC | Tgzzzyfcn | Pztbqft | $105.0 Bil | |
BSX
| Boston Scientific Corp | Vzwqshl | Vmgjnxz | $99.9 Bil | |
EW
| Edwards Lifesciences Corp | Fsxvcmqzcw | Xndzhjv | $52.5 Bil | |
DXCM
| DexCom Inc | Hqqbvtwx | Jbqf | $51.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Zhynxzrpd | Pgk | $24.9 Bil | |
ALGN
| Align Technology Inc | Wmfhrvrp | Qjfpq | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Tffvqnhf | Ynlvhqk | $18.2 Bil | |
PODD
| Insulet Corp | Yrpnysbgr | Tsdwyg | $11.6 Bil |